With the number of targets in gastrointestinal cancer growing, particularly KRAS in colorectal cancer and tumor mutational burden across all gastrointestinal tumors, Andrea Cercek, MD, sought to provide an overview of current and emerging targets during the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.
Lisaftoclax, a BCL-2 inhibitor, demonstrated efficacy and tolerability in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma as well as amyloidosis.
Olverembatinib demonstrates potential as a safe, effective second-line therapy for chronic-phase CML after resistance to second-generation TKIs, according to ChiCTR2200061655 trial data.
The induction regimen of isatuximab plus RVd significantly improved progression-free survival vs RVd alone in transplant-eligible patients with newly diagnosed multiple myeloma.
In a retrospective cohort of patients with central nervous system manifestations of multiple myeloma, ide-cel CAR T-cell therapy was effective.
Elizabeth A. Brem, MD, discusses treatment options for patients with diffuse large B-cell lymphoma.
Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment discontinuation rates vs investigator’s choice in previously treated CLL/SLL.
Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.
The phase 3 IMROZ trial showed isatuximab plus VRd and Rd maintenance improved MRD negativity and responses versus VRd alone in transplant-ineligible newly diagnosed multiple…
An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights predictive biomarkers for improved triple-negative breast cancer outcomes.
The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and other areas by adding pelabresib to a…
